The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; part 3 - study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT 1 steroids vs MDT alone, assessed at 6 months post - release from 12 months MDT

Leprosy Review

Volumn 81, Issue 1, 2010, Pages 41-58

  Shetty, Vanaja Prabhakar ^a   Khambati, Fatema Abbas ^a   Ghate, Sunil Dattatraya ^a   Capadia, Gospi Dolly ^a   Pai, Vivek Vasudev ^b   Ganapati, Ramaswamy ^b  

^a FOUNDATION FOR MEDICAL RESEARCH   (India)

^b Bombay Leprosy Project   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CORTICOSTEROID; LEPROSTATIC AGENT; PREDNISOLONE;

ADULT; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOLOGY; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG USE; FEMALE; GRANULOMA; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOON FACE; MOTOR NERVE; MULTIBACILLARY LEPROSY; MYCOBACTERIUM LEPRAE; NERVE CONDUCTION; NERVE FUNCTION; NERVE INJURY; NEURITIS; NEUROPATHY; NONHUMAN; PALPATION; REMISSION; REVERSAL REACTION; SENSORY NERVE; SIDE EFFECT; SMEAR; WEIGHT GAIN; DRUG COMBINATION; DRUG EFFECT; FOLLOW UP; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGY; NEUROLOGIC EXAMINATION; PATHOLOGY; PATHOPHYSIOLOGY; PERIPHERAL NERVE; PERIPHERAL NEUROPATHY; PROSPECTIVE STUDY; SKIN; TIME; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEPROSTATIC AGENTS; LEPROSY, MULTIBACILLARY; MALE; MYCOBACTERIUM LEPRAE; NEUROLOGIC EXAMINATION; PERIPHERAL NERVES; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; SKIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953144313     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Lockwood DNJ. Steroids in leprosy type 1 (reversal) reactions: mechanisms of action and effectiveness. Lepr Rev, 2000; 71: S111-S114.
2. Naafs B. Treatment of reactions and nerve damage. Int J Lepr, 1996; 64: S21-S28.
3. Kiran KU, Stanley JN, Pearson JM. The outpatient treatment of nerve damage in patients with borderline leprosy using a semi-standardized steroid regimen. Lepr Rev, 1985; 56: 127-134.
4. Britton WJ. The management of leprosy reversal reactions. Lepr Rev, 1981; 69: 225-234.
5. Naafs B. Treatment duration of reversal reaction: a re-appraisal. Back to the past. Lepr Rev, 2003; 74: 328-336.
6. Sundar Rao PSS, Sugamaran DST, Richard J, Smith WCS. Multi-centric, double blind, randomized trial of three steroid regimens in the treatment of type 1 reactions in leprosy. Lepr Rev, 2006; 77: 25-33.
7. Kumar B, Dogra S, Inderjeet K. Epidemiological characteristics of leprosy reactions: 15 years experience from North India. Int J Lepr, 2004; 72: 125-133.
8. Waters MRF. Relapse following various types of multidrug therapy in multibacillary leprosy. Editorial Lepr Rev, 1995; 66: 1-9.
9. Girdhar BK, Girdhar A, Kumar A. Relapses in multibacillary leprosy patient: effect of length at therapy. Lepr Rev, 2000; 71: 144-153.
10. Shetty VP, Wakade AV, Antia NH. A high incidence of viable Mycobacterium leprae in post- MDT recurrent lesions in tuberculoid leprosy patients. Lepr Rev, 2001; 72: 337-344.
11. Shetty VP, Wakade AV, Ghate SD, Pai VV, Ganapati RR, Antia NH. Clinical, histopathological and bacteriological study of 52 referral MB cases relapsing after MDT. Lepr Rev, 2005; 76: 241-252.
12. Wayne LG. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur JClin Microbiol Dis, 1994; 13: 908-914.
13. Jamet P, Ji B, Marchoux chemotherapy study group. Relapse after long term follow up of multibacillary patient treated by WHO multidrug regimen. Int J Lepr, 1995; 63: 195-201.
14. Shetty VP, Uplekar MW, Antia NH. Immunohistological localization of mycobacterial antigens within the peripheral nerves of treated leprosy patients and their significance to nerve damage in leprosy. Acta Neuropathol, 1994; 88: 300-306.
15. Khambati FA, Shetty VP, Ghate SD, Capadia GD, Pai VV, Ganapati R. The effect of corticosteroid usage on the bacterial killing, clearance and nerve damage in leprosy. A prospective cohort study: Part 1 - study design and baseline findings of 400 multibacillary patients. Lepr Rev, 2008; 79: 1-21.
16. Croft RP, Nichollas PG, Richardus JH, Smith WCS. Incidence of acute nerve function impairment in leprosy: a prospective cohort analysis after 24 months (The Bangladesh acute nerve damage study). Lepr Rev, 2000; 71: 18-23.
17. WHO. Study group on chemotherapy of leprosy for control programmes, 1982; TRS, 675; 1-33.
18. Ridley DS, Jopling WH. Classification of leprosy according to immunity - A five group system. Int J Lepr, 1966; 34: 255-273.
19. WHO expert committee on leprosy, WHO technical report series, 1998, No. 874.
20. Khambati FA, Shetty VP, Ghate SD, Capadia GD. Sensitivity and specificity of nerve palpation, monofilament testing and voluntary muscle in detecting peripheral nerve abnormality, using nerve conduction studies as gold standard; A study in 357 patients. Lepr Rev, 2009; 80: 34-50.
21. Little D, Kanolkar-Young S, Coulthart A et al. Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin -12 and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during Prednisolone treatment. Infect Immun, 2001; 69: 3413-3417.
22. Ridley MJ, Waters MFR, Ridley DS. Events surrounding the recognition of Mycobacterium leprae in nerves. Int J Lepr, 1987; 55: 99-108.
23. WHO. Laboratory techniques for leprosy, 1987; WHO/CDS/LEP/86.4.
24. Richardus JH, Withington SG, Anderson AM et al. Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy; results from the TRIPOD trial. Lepr Rev, 2003; 74: 319-327.
25. Rees RJW. Limited multiplication of acid fast bacilli in the foot pads of mice inoculated with Mycobacterium leprae. Br J Path, 1964; 45: 207-218.
26. Toman K. Bacterial persistence in leprosy. Int J Lepr, 1981; 49: 205-216.
27. Waters MRF. Relapse following various types of multi-drug therapy in multibacillary leprosy. Editorial Lepr Rev, 1995; 66: 1-9.
28. Modlin RL, Kaplan JM, Young SM et al. Learning from lesions: patterns of tissue inflammation in leprosy. Proc Nat Acad Sci, 1988; 84: 1213-1217.
29. van Brakel WH, Khawas IB. Nerve function impairment in leprosy: an epidemiological and clinical study-Part 2; results of steroid treatment. Lepr Rev, 1996; 67: 104-118.
30. Smith WCS, Anderson AM, Withington SG et al. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomized placebo controlled trial (TRIPOD 1). BMJ, 2004; 328: 1459.
31. Sehgal VN, Srivastava G, Sundharam JA. Immunology of reactions in leprosy. Int J Dermatol, 1988; 27: 157-162.
32. Ochoa MT, Stenger S, Sieling P et al. T - cell release of granuloma contributes to host defense in leprosy. Nature Med, 2001; 7: 174-179.
33. Van Brakel WH, Nicholls PG, Das L, Barkataki P. The INFIR Cohort study: Investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in North India. Lepr Rev, 2005; 76: 14-34.
34. Garbino JA, Virmond M da CL, Ura S et al. A randomized clinical trial of oral steroids for ulnar neuropathy in type 1 and 2 leprosy reactions. Arq Neuropsiquiatr, 2008; 66: 861-867.
35. Naafs B. Treatment of leprosy: science or politics? Trop Med Int Health, 2006; 11: 268-278.